European Commission Approves Innovative CAR T-cell Therapy Pioneered at Children’s Hospital of Philadelphia
Published on
The European Commission (EC) approves Kymriah, the first-ever U.S. FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers.